References
- Hama R. The mechanisms of delayed onset type adverse reactions to oseltamivir. Infect Dis. 2016;48:651–660.
- Jefferson T. The neuraminidase inhibitors evidence of harms – in context. Infect Dis. 2016;48:661–662.
- Qiu S, Shen Y, Pan H, et al. Effectiveness and safety of oseltamivir for treating influenza: an updated meta-analysis of clinical trials. Infect Dis. 2015;47:808–819.
- Hikita T, Hikita H, Hikita F, et al. Clinical effectiveness of peramivir in comparison with other neuraminidase inhibitors in pediatric influenza patients. Int J Pediatr. 2012;2012:834181
- Shobugawa Y, Saito R, Sato I, et al. Clinical effectiveness of neuraminidase inhibitors–oseltamivir, zanamivir, laninamivir, and peramivir–for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan. J Infect Chemother. 2012;18:858–864.
- Yoshino Y, Seo K, Koga I, et al. Clinical efficacy of peramivir in adult patients with seasonal influenza during the winter of 2012 in Japan. Clin Respir J. 2015;9:228–232.
- Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother. 2010;54:2575–2582.
- Takemoto Y, Asai T, Ikezoe I, et al. Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012–2013. Chemotherapy. 2013;59:373–378.
- Koseki N, Kaiho M, Kikuta H, et al. Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011–2012 season. Influenza Other Respir Viruses. 2014;8:151–158.
- Kohno S, Yen MY, Cheong HJ, et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother. 2011;55:5267–5276.